MedTrace Logo

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

NCT00073749 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2018-12-17

Study results available
· View outcomes & findings →

Summary

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Conditions

  • Lymphoma, B-Cell

Interventions

DRUG

Inotuzumab ozogamicin [CMC-544]

CMC-544, IV, dose escalation trial

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073749 on ClinicalTrials.gov